Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inspira Technologies Oxy BHN ( (IINN) ) has shared an announcement.
On December 23, 2025, Inspira Technologies Oxy B.H.N. Ltd. reaffirmed that previously announced binding purchase orders totaling $49.5 million remain valid and in full force, based on confirmations from its distribution partner. The company said the payment and execution framework for these orders has been rescheduled to begin with the 2026 fiscal year, aligning cash collection and revenue recognition with regulatory sequencing, technical implementation needs, and institutional funding timelines for large-scale international healthcare deployments. By coordinating closely with regulators, distribution partners, and funding organizations, Inspira aims to reduce execution risk, improve operational visibility, and support a phased rollout of its technologies across target markets, with further updates expected as 2026 regulatory and deployment milestones are reached.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., and serves as the platform for the next-generation INSPIRA ART500, designed to provide oxygenation to awake, spontaneously breathing patients. The company is also developing HYLA, a proprietary blood sensor platform for continuous, non-invasive monitoring, and is positioning itself as a streamlined, IP-rich player in the life-support and broader MedTech market.
Average Trading Volume: 202,416
Technical Sentiment Signal: Sell
Current Market Cap: $36.43M
Find detailed analytics on IINN stock on TipRanks’ Stock Analysis page.